Patent details
300957
Product Name:
Een combinatie omvattende dolutegravir of een farmaceutisch aanvaardbaar zout daarvan (zoals dolutegravir natrium) en rilpivirine of een farmaceutisch aanvaardbaar zout daarvan (zoals rilpivirine hydrochloride).
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300957
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2932970
Status:
Refused Art. 10 of the EC Regulations
Application number:
300957
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/18/1282
Marketing Authorization Type:
EEA
Marketing Authorization Date:
18/05/2018
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
07/11/2018
First Marketing Authorization date:
18/05/2018
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
12/11/2018
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
24/12/2024
Applicant/holder
From:
07/11/2018
Name:
VIIV Healthcare Company
Address:
251 Little Falls Drive, 19808, Wilmington, DE , United States of America (US)
Agent
Name:
ir. H.A. Witmans c.s.
From:
07/11/2018
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
52/24
Publication date:
08/01/2025
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
47/18
Publication date:
14/11/2018
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
24/12/2024
Outgoing Correspondence
Decision refusal
2
PDF
/8/1/9/7/3/0800337918/docs/300957_9_637074l527a.pdf
13/06/2024
Outgoing Correspondence
Letter to applicant
2
PDF
/8/1/9/7/3/0800337918/docs/300957_8_607742l173.pdf
12/11/2018
Outgoing Correspondence
Confirmation receipt request
1
PDF
/8/1/9/7/3/0800337918/docs/300957_7_239010l174.pdf
07/11/2018
SPC Documents
Annex SPC
2
PDF
/8/1/9/7/3/0800337918/docs/300957_0_supplprotectioncertificate20181112121657924.pdf
07/11/2018
Application Form
First filed application form
3
PDF
/8/1/9/7/3/0800337918/docs/300957_1_applicationform20181112121657472.pdf
07/11/2018
SPC Documents
Marketing Authorization SPC
3
PDF
/8/1/9/7/3/0800337918/docs/300957_2_supplprotectioncertificate20181112121657776.pdf
07/11/2018
SPC Documents
Accompanying letter SPC
2
PDF
/8/1/9/7/3/0800337918/docs/300957_3_supplprotectioncertificate20200922011616770.pdf
07/11/2018
SPC Documents
Annex SPC
1
PDF
/8/1/9/7/3/0800337918/docs/300957_4_supplprotectioncertificate20200527040738526.pdf
07/11/2018
SPC Documents
Annex SPC
20
PDF
/8/1/9/7/3/0800337918/docs/300957_5_supplprotectioncertificate20181112121657987.pdf
07/11/2018
SPC Documents
Summary of the characteristics of the product
32
PDF
/8/1/9/7/3/0800337918/docs/300957_6_supplprotectioncertificate20181112033209288.pdf